InvestingPro’s fair value model captured ImmunityBio’s 45% downside

InvestingPro's fair value model has revealed a significant downside for ImmunityBio, estimating a 45% drop in its stock value. This finding is crucial for investors as it highlights potential risks associated with the company, prompting a reevaluation of investment strategies. Understanding these projections can help stakeholders make informed decisions in a volatile market.